Escitalopram: a Review of Its Use in the Management of Anxiety Disorders

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2006 Sep 7

PMID 16953656

Citations 14

Authors

Sohita Dhillon

Lesley J Scott

Greg L Plosker

Affiliations

Soon will be listed here.

Abstract

Escitalopram (Cipralex, Lexapro, Seroplex, Sipralexa), the therapeutically active S-enantiomer of racemic citalopram (RS-citalopram), is a potent and highly selective serotonin reuptake inhibitor. It is effective and generally well tolerated in the treatment of moderate to severe generalised anxiety disorder (GAD) or social anxiety disorder (SAD), panic disorder (with or without agoraphobia) as well as obsessive-compulsive disorder (OCD). Moreover, escitalopram is at least as effective as paroxetine for the treatment of GAD, SAD or OCD and appears to achieve a more rapid response than racemic citalopram in the management of panic disorder. Generally, it has a more favourable tolerability profile than paroxetine in terms of fewer discontinuation symptoms. In addition, a favourable pharmacokinetic profile permits once-daily administration of the drug. Additional comparative studies are required to definitively position escitalopram with respect to other SSRIs and venlafaxine. Nevertheless, available clinical data indicate that escitalopram is an effective first-line treatment option for the management of GAD, SAD, panic disorder and OCD.

Citing Articles

Synthesis of anti-depressant molecules metal-catalyzed reactions: a review.

Kanwal A, Afzal U, Zubair M, Imran M, Rasool N RSC Adv. 2024; 14(10):6948-6971.

PMID: 38410364 PMC: 10895647. DOI: 10.1039/d3ra06391g.

Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age.

Liu S, Xiao T, Huang S, Li X, Kong W, Yang Y Front Pharmacol. 2022; 13:964758.

PMID: 35924062 PMC: 9340256. DOI: 10.3389/fphar.2022.964758.

Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design.

Foudah A, Alshehri S, Shakeel F, Alqarni M, Aljarba T, Alam P Molecules. 2022; 27(13).

PMID: 35807458 PMC: 9268709. DOI: 10.3390/molecules27134209.

Ru-Catalyzed Asymmetric Addition of Arylboronic Acids to Aliphatic Aldehydes via -Chiral Monophosphorous Ligands.

Miao R, Xia Y, Wei Y, Ouyang L, Luo R Molecules. 2022; 27(12).

PMID: 35745017 PMC: 9231018. DOI: 10.3390/molecules27123898.

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.

Kirino E Patient Prefer Adherence. 2012; 6:853-61.

PMID: 23271894 PMC: 3526882. DOI: 10.2147/PPA.S22495.

References

Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine J . Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004; 291(21):2581-90. DOI: 10.1001/jama.291.21.2581. View

Parker G, Tully L, Olley A, Hadzi-Pavlovic D . SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. J Affect Disord. 2006; 92(2-3):205-14. DOI: 10.1016/j.jad.2006.01.024. View

Fonseca M, Soares J, Hatch J, Santin A, Kapczinski F . An open trial of adjunctive escitalopram in bipolar depression. J Clin Psychiatry. 2006; 67(1):81-6. DOI: 10.4088/jcp.v67n0115. View

Sogaard B, Mengel H, Rao N, Larsen F . The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005; 45(12):1400-6. DOI: 10.1177/0091270005280860. View

Belzer K, Schneier F . Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract. 2004; 10(5):296-306. DOI: 10.1097/00131746-200409000-00003. View

Kasper S, Stein D, Loft H, Nil R . Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005; 186:222-6. DOI: 10.1192/bjp.186.3.222. View

Murdoch D, Keam S . Escitalopram: a review of its use in the management of major depressive disorder. Drugs. 2005; 65(16):2379-404. DOI: 10.2165/00003495-200565160-00013. View

Sanchez C, Bergqvist P, Brennum L, Gupta S, Hogg S, Larsen A . Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003; 167(4):353-62. DOI: 10.1007/s00213-002-1364-z. View

Davidson J, Bose A, Korotzer A, Zheng H . Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004; 19(4):234-40. DOI: 10.1002/da.10146. View

10.

Uys J, Muller C, Marais L, Harvey B, Stein D, Daniels W . Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram. Neuroscience. 2005; 137(2):619-25. DOI: 10.1016/j.neuroscience.2005.08.089. View

11.

Fish E, Faccidomo S, Gupta S, Miczek K . Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups. J Pharmacol Exp Ther. 2003; 308(2):474-80. DOI: 10.1124/jpet.103.058206. View

12.

Culpepper L . Identifying and treating panic disorder in primary care. J Clin Psychiatry. 2004; 65 Suppl 5:19-23. View

13.

Gunnell D, Saperia J, Ashby D . Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005; 330(7488):385. PMC: 549105. DOI: 10.1136/bmj.330.7488.385. View

14.

Lader M, Stender K, Burger V, Nil R . Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004; 19(4):241-8. DOI: 10.1002/da.20014. View

15.

Olesen O, Linnet K . Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology. 1999; 59(6):298-309. DOI: 10.1159/000028333. View

16.

Goodman W, Bose A, Wang Q . Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005; 87(2-3):161-7. DOI: 10.1016/j.jad.2004.11.011. View

17.

Bielski R, Bose A, Chang C . A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005; 17(2):65-9. DOI: 10.1080/10401230590932326. View

18.

Rampono J, Kristensen J, Hackett L, Paech M, Kohan R, Ilett K . Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol. 2000; 50(3):263-8. PMC: 2014979. DOI: 10.1046/j.1365-2125.2000.00253.x. View

19.

Montgomery S, Lecrubier Y, Baldwin D, Kasper S, Lader M, Nil R . ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. Eur Neuropsychopharmacol. 2004; 14(5):425-33. DOI: 10.1016/j.euroneuro.2004.06.001. View

20.

Sanchez C, Gruca P, Papp M . R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol. 2003; 14(5-6):465-70. DOI: 10.1097/01.fbp.0000087733.21047.60. View